CCM
TEVA icon

CAAS Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

CAAS Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-106,400
Closed -$1.2M – 478
2020
Q1 		$955K Buy
+106,400
New +$1.09M 0.1% 140

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

CAAS Capital Management's TEVA Position: Q2 2020 in Review

CAAS Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2020, closing a stake of 106,400 shares — an estimated $1.2M sold.

CAAS Capital Management first reported a position in TEVA in Q1 2020 and held it in 1 quarter. The position peaked at $955K in Q1 2020. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • CAAS Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • CAAS Capital Management sold 106,400 Teva Pharmaceuticals shares in Q2 2020, an estimated $1.2M.
  • CAAS Capital Management first reported a position in Teva Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • CAAS Capital Management's Teva Pharmaceuticals position peaked at $955K in Q1 2020.
  • 455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on CAAS Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.